The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Patient-reported outcomes in a randomized phase 1 dose‑expansion study of mevrometostat (M), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide (E) in patients with metastatic castration‑resistant prostate cancer (mCRPC)
Schweizer M, Calvo M, Moreno V, Mellado B, Castellano D, Spira A, Wei Q, Carels J, Garmezy B, Kwak C, Lugowska I, Penkov K, Shore ND, Tougias J, Andreu-Vieyra C, Niyazov A, Soman N, Gordoa TA
Mevrometostat (PF-06821497) | October 18, 2025 | ESMO 2025
C2321001 | NCT03460977
Poster
Safety and pharmacokinetics of mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Matsubara N, Ayanambakkam A, Carles J, Zhang T , Mellado B, Moreno V, Velasco G, Dunshee C, Schweizer M, Qiang W, Garmezy B, Mittapalli R, Tougias J, Andreu-Vieyra C, Soman N, Gordoa TA
Mevrometostat (PF-06821497) | June 2, 2025 | ASCO 2025
C2321001 | NCT03460977
Presentation
Mevrometostat (PF-06821497), an EZH2 inhibitor, in combination with enzalutamide in patients with mCRPC: A randomized dose-expansion study
Schweizer M, Calvo M, Moreno V, Mellado B, Castellanos D, Spira A, Wei Q, Carles J, Garmezy B, Kwak C, Ługowska I, Penkov K, Shore N, Liu L, Mittapalli R, Tougias J, Andreu-Vieyra C, Soman N, Gordoa TA
Mevrometostat (PF-06821497) | February 13, 2025 | ASCO GU 2025
C2321001 | NCT03460977
Poster
Mevrometostat (PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 trial
Schweizer M, Chakrabarti J, Narayanan S, Lin S
Mevrometostat (PF-06821497) | February 13, 2025 | ASCO GU 2025
C2321003 | NCT06629779
Poster
Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic markers and tumor gene expression by mevrometostat (PF-06821497) in combination with enzalutamide in patients with castration‑resistant prostate cancer (CRPC)
Schweizer MT, Liu L, Tang SY, Roh W, Bonato V, Carles J, Garmezy B, Dunshee CJ, de Velasco G, Penkov K, Andreu-Vieyra C, Soman N, Mellado-González B
Mevrometostat (PF-06821497) | February 13, 2025 | ASCO GU 2025
C2321001 | NCT03460977
Poster
Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration‑resistant prostate cancer previously treated with abiraterone: The phase 3, randomized MEVPRO‑1 study
Agarwal N, Schweizer M, Castro E, Azad A, George DJ, Chakrabarti J, Narayanan S, Tang Y, Fizazi K
Mevrometostat (PF-06821497) | December 4, 2024 | SUO 2024
C2321014 | NCT06551324
Poster
Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC)
Schweizer MT, Penkov K, Choudhury A, EC Aller, Frank R, Liu L, Mittapalli R, Tougias J, Andreu-Vieyra C, Bowler T, Soman N, Johnson M
Mevrometostat (PF-06821497) | May 31, 2024 | ASCO 2024
C2321001 | NCT03460977